- Home
- FMST vs APM Comparison
FMST vs APM Comparison
Compare FMST & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- APM
- Stock Information
- Founded
- FMST 2005
- APM 2010
- Country
- FMST Canada
- APM United Kingdom
- Employees
- FMST N/A
- APM N/A
- Industry
- FMST Other Metals and Minerals
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- APM Health Care
- Exchange
- FMST Nasdaq
- APM Nasdaq
- Market Cap
- FMST 7.1M
- APM 6.1M
- IPO Year
- FMST N/A
- APM 2018
- Fundamental
- Price
- FMST $3.31
- APM $0.94
- Analyst Decision
- FMST
- APM
- Analyst Count
- FMST 0
- APM 0
- Target Price
- FMST N/A
- APM N/A
- AVG Volume (30 Days)
- FMST 1.1M
- APM 91.6K
- Earning Date
- FMST 01-01-0001
- APM 07-07-2025
- Dividend Yield
- FMST N/A
- APM N/A
- EPS Growth
- FMST N/A
- APM N/A
- EPS
- FMST N/A
- APM N/A
- Revenue
- FMST N/A
- APM N/A
- Revenue This Year
- FMST N/A
- APM N/A
- Revenue Next Year
- FMST N/A
- APM N/A
- P/E Ratio
- FMST N/A
- APM N/A
- Revenue Growth
- FMST N/A
- APM N/A
- 52 Week Low
- FMST $0.55
- APM $0.46
- 52 Week High
- FMST $5.74
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- FMST 56.55
- APM 47.58
- Support Level
- FMST $3.27
- APM $1.01
- Resistance Level
- FMST $3.78
- APM $1.06
- Average True Range (ATR)
- FMST 0.53
- APM 0.10
- MACD
- FMST -0.12
- APM -0.02
- Stochastic Oscillator
- FMST 27.69
- APM 15.68
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.